60 95

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Authors
 Taroh Satoh  ;  Kyung Hee Lee  ;  Sun Young Rha  ;  Yasutsuna Sasaki  ;  Se Hoon Park  ;  Yoshito Komatsu  ;  Hirofumi Yasui  ;  Tae-You Kim  ;  Kensei Yamaguchi  ;  Nozomu Fuse  ;  Yasuhide Yamada  ;  Takashi Ura  ;  Si-Young Kim  ;  Masaki Munakata  ;  Soh Saitoh  ;  Kazuto Nishio  ;  Satoshi Morita  ;  Eriko Yamamoto  ;  Qingwei Zhang  ;  Jung-mi Kim  ;  Yeul Hong Kim  ;  Yuh Sakata 
Citation
 Gastric Cancer, Vol.18(4) : 824-832, 2015 
Journal Title
 Gastric Cancer 
ISSN
 1436-3291 
Issue Date
2015
Abstract
BACKGROUND: This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. METHODS: Irinotecan-naive patients (n = 82) received N-IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m(2) biweekly) or IRI (irinotecan 150 mg/m(2) biweekly) until disease progression. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), response rate (RR), safety, tolerability, and the correlation between efficacy and tumor epidermal growth factor receptor (EGFR) expression. RESULTS: Of 83 patients, 40 and 43 patients were randomly assigned to the N-IRI and IRI groups, respectively. In the N-IRI/IRI treatment group, median PFS was 73.0/85.0 days (P = 0.5668), and median OS and RR at 18 months were 250.5/232.0 days (P = 0.9778) and 18.4/10.3 %, respectively. Median PFS and OS in the EGFR 2+/3+ subgroups were 118.5/59.0 and 358.5/229.5 days, respectively. The RR was 33.3/0.0 % in the N-IRI/IRI treatment group. The incidence of grade 3 or higher adverse events was 77.5/64.3 %. No adverse events of grade 3 or higher skin rash or grade 3 or higher infusion-related reaction were reported. CONCLUSIONS: There was no superiority of N-IRI over IRI alone in terms of PFS in 5-fluorouracil-refractory AGC patients. However, N-IRI showed potential improvement in the EGFR 2+/3+ subgroup based on improved RR, PFS, and OS.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/141623
Files in This Item:
T201504079.pdf Download
DOI
10.1007/s10120-014-0420-9
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
라선영(Rha, Sun Young)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse